127 related articles for article (PubMed ID: 38417135)
1. Mutant U2AF1-Induced Mis-Splicing of mRNA Translation Genes Confers Resistance to Chemotherapy in Acute Myeloid Leukemia.
Jin P; Wang X; Jin Q; Zhang Y; Shen J; Jiang G; Zhu H; Zhao M; Wang D; Li Z; Zhou Y; Li W; Zhang W; Liu Y; Wang S; Jin W; Cao Y; Sheng G; Dong F; Wu S; Li X; Jin Z; He M; Liu X; Chen L; Zhang Y; Wang K; Li J
Cancer Res; 2024 May; 84(10):1583-1596. PubMed ID: 38417135
[TBL] [Abstract][Full Text] [Related]
2. Precision analysis of mutant U2AF1 activity reveals deployment of stress granules in myeloid malignancies.
Biancon G; Joshi P; Zimmer JT; Hunck T; Gao Y; Lessard MD; Courchaine E; Barentine AES; Machyna M; Botti V; Qin A; Gbyli R; Patel A; Song Y; Kiefer L; Viero G; Neuenkirchen N; Lin H; Bewersdorf J; Simon MD; Neugebauer KM; Tebaldi T; Halene S
Mol Cell; 2022 Mar; 82(6):1107-1122.e7. PubMed ID: 35303483
[TBL] [Abstract][Full Text] [Related]
3. Alteration of the SETBP1 gene and splicing pathway genes SF3B1, U2AF1, and SRSF2 in childhood acute myeloid leukemia.
Choi HW; Kim HR; Baek HJ; Kook H; Cho D; Shin JH; Suh SP; Ryang DW; Shin MG
Ann Lab Med; 2015 Jan; 35(1):118-22. PubMed ID: 25553291
[TBL] [Abstract][Full Text] [Related]
4. Mutant U2AF1 Expression Alters Hematopoiesis and Pre-mRNA Splicing In Vivo.
Shirai CL; Ley JN; White BS; Kim S; Tibbitts J; Shao J; Ndonwi M; Wadugu B; Duncavage EJ; Okeyo-Owuor T; Liu T; Griffith M; McGrath S; Magrini V; Fulton RS; Fronick C; O'Laughlin M; Graubert TA; Walter MJ
Cancer Cell; 2015 May; 27(5):631-43. PubMed ID: 25965570
[TBL] [Abstract][Full Text] [Related]
5. U2AF1 mutation promotes tumorigenicity through facilitating autophagy flux mediated by FOXO3a activation in myelodysplastic syndromes.
Zhu Y; Song D; Guo J; Jin J; Tao Y; Zhang Z; Xu F; He Q; Li X; Chang C; Wu L
Cell Death Dis; 2021 Jun; 12(7):655. PubMed ID: 34183647
[TBL] [Abstract][Full Text] [Related]
6. Mutant U2AF1-expressing cells are sensitive to pharmacological modulation of the spliceosome.
Shirai CL; White BS; Tripathi M; Tapia R; Ley JN; Ndonwi M; Kim S; Shao J; Carver A; Saez B; Fulton RS; Fronick C; O'Laughlin M; Lagisetti C; Webb TR; Graubert TA; Walter MJ
Nat Commun; 2017 Jan; 8():14060. PubMed ID: 28067246
[TBL] [Abstract][Full Text] [Related]
7. Impaired hematopoiesis and leukemia development in mice with a conditional knock-in allele of a mutant splicing factor gene
Fei DL; Zhen T; Durham B; Ferrarone J; Zhang T; Garrett L; Yoshimi A; Abdel-Wahab O; Bradley RK; Liu P; Varmus H
Proc Natl Acad Sci U S A; 2018 Oct; 115(44):E10437-E10446. PubMed ID: 30322915
[TBL] [Abstract][Full Text] [Related]
8. Ribosome biogenesis is a downstream effector of the oncogenic U2AF1-S34F mutation.
Akef A; McGraw K; Cappell SD; Larson DR
PLoS Biol; 2020 Nov; 18(11):e3000920. PubMed ID: 33137094
[TBL] [Abstract][Full Text] [Related]
9. [Clinical Characteristics and Prognosis of U2AF1 Mutation in Patients with Acute Myeloid Leukemia].
Zhao TY; Guan LX; Zheng WS; Wang ML; Cheng LC; Hu YL; Xu YY; Gu ZY; Dou LP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Feb; 28(1):7-11. PubMed ID: 32027245
[TBL] [Abstract][Full Text] [Related]
10. Splicing factor mutations predict poor prognosis in patients with de novo acute myeloid leukemia.
Hou HA; Liu CY; Kuo YY; Chou WC; Tsai CH; Lin CC; Lin LI; Tseng MH; Chiang YC; Liu MC; Liu CW; Tang JL; Yao M; Li CC; Huang SY; Ko BS; Hsu SC; Chen CY; Lin CT; Wu SJ; Tsay W; Tien HF
Oncotarget; 2016 Feb; 7(8):9084-101. PubMed ID: 26812887
[TBL] [Abstract][Full Text] [Related]
11. U2AF1 mutations induce oncogenic IRAK4 isoforms and activate innate immune pathways in myeloid malignancies.
Smith MA; Choudhary GS; Pellagatti A; Choi K; Bolanos LC; Bhagat TD; Gordon-Mitchell S; Von Ahrens D; Pradhan K; Steeples V; Kim S; Steidl U; Walter M; Fraser IDC; Kulkarni A; Salomonis N; Komurov K; Boultwood J; Verma A; Starczynowski DT
Nat Cell Biol; 2019 May; 21(5):640-650. PubMed ID: 31011167
[TBL] [Abstract][Full Text] [Related]
12. A pan-cancer analysis of transcriptome changes associated with somatic mutations in U2AF1 reveals commonly altered splicing events.
Brooks AN; Choi PS; de Waal L; Sharifnia T; Imielinski M; Saksena G; Pedamallu CS; Sivachenko A; Rosenberg M; Chmielecki J; Lawrence MS; DeLuca DS; Getz G; Meyerson M
PLoS One; 2014; 9(1):e87361. PubMed ID: 24498085
[TBL] [Abstract][Full Text] [Related]
13. The splicing factor U2AF1 contributes to cancer progression through a noncanonical role in translation regulation.
Palangat M; Anastasakis DG; Fei DL; Lindblad KE; Bradley R; Hourigan CS; Hafner M; Larson DR
Genes Dev; 2019 May; 33(9-10):482-497. PubMed ID: 30842218
[TBL] [Abstract][Full Text] [Related]
14. Wild-Type U2AF1 Antagonizes the Splicing Program Characteristic of U2AF1-Mutant Tumors and Is Required for Cell Survival.
Fei DL; Motowski H; Chatrikhi R; Prasad S; Yu J; Gao S; Kielkopf CL; Bradley RK; Varmus H
PLoS Genet; 2016 Oct; 12(10):e1006384. PubMed ID: 27776121
[TBL] [Abstract][Full Text] [Related]
15. Nonsense-Mediated RNA Decay Is a Unique Vulnerability of Cancer Cells Harboring
Cheruiyot A; Li S; Nonavinkere Srivatsan S; Ahmed T; Chen Y; Lemacon DS; Li Y; Yang Z; Wadugu BA; Warner WA; Pruett-Miller SM; Obeng EA; Link DC; He D; Xiao F; Wang X; Bailis JM; Walter MJ; You Z
Cancer Res; 2021 Sep; 81(17):4499-4513. PubMed ID: 34215620
[TBL] [Abstract][Full Text] [Related]
16. U2AF1 mutations in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome.
Qian J; Yao DM; Lin J; Qian W; Wang CZ; Chai HY; Yang J; Li Y; Deng ZQ; Ma JC; Chen XX
PLoS One; 2012; 7(9):e45760. PubMed ID: 23029227
[TBL] [Abstract][Full Text] [Related]
17. U2AF1 pathogenic variants in myeloid neoplasms and precursor states: distribution of co-mutations and prognostic heterogeneity.
Badar T; Vanegas YAM; Nanaa A; Foran JM; Al-Kali A; Mangaonkar A; Murthy H; Alkhateeb HB; Viswanatha D; He R; Shah M; Yi CA; Litzow MR; Gangat N; Tefferi A; Patnaik MM
Blood Cancer J; 2023 Sep; 13(1):149. PubMed ID: 37735430
[TBL] [Abstract][Full Text] [Related]
18. Mutant U2AF1-induced differential alternative splicing causes an oxidative stress in bone marrow stromal cells.
Liu Z; Dong X; Cao Z; Qiu S; Li Y; Zhong M; Xue Z; Xu Y; Xing H; Tang K; Tian Z; Wang M; Rao Q; Wang J
Exp Biol Med (Maywood); 2021 Aug; 246(15):1750-1759. PubMed ID: 34034558
[TBL] [Abstract][Full Text] [Related]
19. Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax.
Lachowiez CA; Loghavi S; Furudate K; Montalban-Bravo G; Maiti A; Kadia T; Daver N; Borthakur G; Pemmaraju N; Sasaki K; Alvarado Y; Yilmaz M; Short NJ; Chien K; Ohanian M; Pierce S; Patel KP; Jabbour E; Ravandi F; Kantarjian HM; Garcia-Manero G; Takahashi K; Konopleva MY; DiNardo CD
Blood Adv; 2021 Apr; 5(8):2173-2183. PubMed ID: 33885753
[TBL] [Abstract][Full Text] [Related]
20. Recurrent SRSF2 mutations in MDS affect both splicing and NMD.
Rahman MA; Lin KT; Bradley RK; Abdel-Wahab O; Krainer AR
Genes Dev; 2020 Mar; 34(5-6):413-427. PubMed ID: 32001512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]